Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Decrease in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 110,600 shares, a drop of 38.1% from the November 30th total of 178,800 shares. Based on an average trading volume of 83,200 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.6% of the shares of the stock are sold short.

Institutional Trading of Aileron Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ALRN. KG&L Capital Management LLC acquired a new position in Aileron Therapeutics during the third quarter worth about $46,000. Warberg Asset Management LLC bought a new stake in shares of Aileron Therapeutics during the 2nd quarter valued at approximately $86,000. Geode Capital Management LLC increased its position in Aileron Therapeutics by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after purchasing an additional 59,370 shares in the last quarter. Sigma Planning Corp lifted its stake in Aileron Therapeutics by 68.3% in the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after purchasing an additional 86,185 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its position in Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after buying an additional 209,367 shares in the last quarter. 90.89% of the stock is currently owned by institutional investors.

Aileron Therapeutics Price Performance

Shares of ALRN opened at $2.25 on Friday. The firm has a 50 day simple moving average of $2.92 and a two-hundred day simple moving average of $2.88. The company has a market cap of $48.75 million, a P/E ratio of -0.72 and a beta of 2.23. Aileron Therapeutics has a one year low of $1.61 and a one year high of $7.42.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).